TET2 and myeloproliferative disorder: Solary et al. (5) reported the highest rate of TET2 genetic alterations was observed in CMML in which a heterozygous or homozygous mutation was identified in 50–60% of this overlapping MDS/MPN; however prognosis associated with prevalence of heterozygous vs. homozygous mutation was not reported.